Compile Data Set for Download or QSAR
Report error Found 59 Enz. Inhib. hit(s) with all data for entry = 11504
TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621214BDBM621214(US20230303584, Compound 311)
Affinity DataIC50: 130nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621186BDBM621186(US20230303584, Compound 254)
Affinity DataIC50: 140nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621203BDBM621203(US20230303584, Compound 294)
Affinity DataIC50: 160nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621191BDBM621191(US20230303584, Compound 266)
Affinity DataIC50: 190nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621222BDBM621222(US20230303584, Compound 321)
Affinity DataIC50: 240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621200BDBM621200(US20230303584, Compound 285)
Affinity DataIC50: 240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621209BDBM621209(US20230303584, Compound 302)
Affinity DataIC50: 250nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621197BDBM621197(US20230303584, Compound 280)
Affinity DataIC50: 260nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621201BDBM621201(US20230303584, Compound 288)
Affinity DataIC50: 270nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621215BDBM621215(US20230303584, Compound 312)
Affinity DataIC50: 280nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621194BDBM621194(US20230303584, Compound 272)
Affinity DataIC50: 300nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621226BDBM621226(US20230303584, Compound 325)
Affinity DataIC50: 320nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621220BDBM621220(US20230303584, Compound 318)
Affinity DataIC50: 330nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621223BDBM621223(US20230303584, Compound 322)
Affinity DataIC50: 340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621225BDBM621225(US20230303584, Compound 324)
Affinity DataIC50: 340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621231BDBM621231(US20230303584, Compound 330)
Affinity DataIC50: 350nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621224BDBM621224(US20230303584, Compound 323)
Affinity DataIC50: 390nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621211BDBM621211(US20230303584, Compound 307)
Affinity DataIC50: 400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621196BDBM621196(US20230303584, Compound 279)
Affinity DataIC50: 400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621212BDBM621212(US20230303584, Compound 308)
Affinity DataIC50: 430nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621206BDBM621206(US20230303584, Compound 298)
Affinity DataIC50: 440nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621187BDBM621187(US20230303584, Compound 255)
Affinity DataIC50: 500nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621188BDBM621188(US20230303584, Compound 256)
Affinity DataIC50: 510nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621208BDBM621208(US20230303584, Compound 301)
Affinity DataIC50: 560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621190BDBM621190(US20230303584, Compound 265)
Affinity DataIC50: 560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621217BDBM621217(US20230303584, Compound 314)
Affinity DataIC50: 560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621229BDBM621229(US20230303584, Compound 328)
Affinity DataIC50: 580nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621219BDBM621219(US20230303584, Compound 317)
Affinity DataIC50: 620nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621189BDBM621189(US20230303584, Compound 264)
Affinity DataIC50: 640nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621234BDBM621234(US20230303584, Compound 336)
Affinity DataIC50: 650nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621230BDBM621230(US20230303584, Compound 329)
Affinity DataIC50: 720nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621193BDBM621193(US20230303584, Compound 271)
Affinity DataIC50: 770nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621228BDBM621228(US20230303584, Compound 327)
Affinity DataIC50: 850nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621199BDBM621199(US20230303584, Compound 284)
Affinity DataIC50: 860nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621227BDBM621227(US20230303584, Compound 326)
Affinity DataIC50: 870nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621240BDBM621240(US20230303584, Compound 353)
Affinity DataIC50: 890nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621192BDBM621192(US20230303584, Compound 267)
Affinity DataIC50: 900nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621210BDBM621210(US20230303584, Compound 304)
Affinity DataIC50: 900nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621221BDBM621221(US20230303584, Compound 319)
Affinity DataIC50: 930nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621233BDBM621233(US20230303584, Compound 335)
Affinity DataIC50: 940nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621241BDBM621241(US20230303584, Compound 354)
Affinity DataIC50: 960nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621195BDBM621195(US20230303584, Compound 277)
Affinity DataIC50: 1.10E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621205BDBM621205(US20230303584, Compound 297)
Affinity DataIC50: 1.40E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621198BDBM621198(US20230303584, Compound 281)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621218BDBM621218(US20230303584, Compound 316)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621236BDBM621236(US20230303584, Compound 342)
Affinity DataIC50: 1.51E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621239BDBM621239(US20230303584, Compound 352)
Affinity DataIC50: 1.56E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621237BDBM621237(US20230303584, Compound 343)
Affinity DataIC50: 1.58E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621216BDBM621216(US20230303584, Compound 313)
Affinity DataIC50: 1.70E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetSmall ubiquitin-related modifier 1(Human)
Suvalent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 621242BDBM621242(US20230303584, Compound 355)
Affinity DataIC50: 1.97E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

Displayed 1 to 50 (of 59 total ) | Next | Last >>
Jump to: